Posthumous assisted reproduction policies among a cohort of United States’ in vitro fertilization clinics

Emma Trawick, M.D., Amani Sampson, B.A., Kara Goldman, M.D., Lisa Campo-Engelstein, Ph.D., Arthur Caplan, Ph.D., David L. Keefe, M.D., and Gwendolyn P. Quinn, Ph.D.

Objective: To assess the presence and content of policies toward posthumous assisted reproduction (PAR) using oocytes and embryos among Society for Assisted Reproductive Technology (SART) member clinics in the United States.

Design: Cross-sectional questionnaire-based study.

Setting: Not applicable.

Patient(s): A total of 62 SART member clinics.

Intervention(s): Questionnaire including multiple choice and open-ended questions.

Main Outcome Measure(s): Descriptive statistics regarding presence and content of policies regarding PAR using oocytes and embryos, consent document content regarding oocyte and embryo disposition, and eligibility of minors and those with terminal illness for fertility preservation.

Result(s): Of the 332 clinics contacted, 62 responded (response rate 18.7%). Respondents were distributed across the United States, and average volume of in vitro fertilization (IVF) cycles per year ranged from <250 to >1,500, but 71.2% (n = 42) reported a volume of <500. Nearly one-half (42.4%, n = 25) of clinics surveyed reported participating in any cases of posthumous reproduction during the past 5 years, and 6.8% (n = 4) reported participation in >5 cases. Participation in cases of posthumous reproduction was not significantly associated with practice type or IVF cycle volume among those surveyed. Only 59.6% (n = 34) of clinics surveyed had written policies regarding PAR using oocytes or embryos, whereas 36.8% (n = 21) reported they did not have a policy. Practice type, IVF cycle volume, fertility preservation volume, and prior participation in cases of PAR were not significantly associated with the presence of a policy among respondent clinics. Of those with a policy, 55.9% (n = 19) reported they had used that policy, 59.1% (n = 13) without a policy reported they had considered adopting one, and 63.6% (n = 14) reported they had received a request for PAR services. Only 47.2% (n = 25) of clinics surveyed specified that patients not expected to survive to use oocytes due to terminal illness are eligible for oocyte cryopreservation, whereas 45.3% (n = 24) did not specify.

Conclusion(s): Respondent clinics reported receiving an increasing number of requests for PAR services, but many also lacked PAR policies. Those with policies did not always follow ASRM recommendations. Given the low response rate, these data cannot be interpreted as representative of SART clinics overall. As PAR cases become more common, however, this study highlights poor reporting of PAR and institutional policies toward PAR, suggesting that SART clinics may not be equipped to systematically manage the complexities of PAR. (Fertil Steril Rep® 2020;1:66–70. © 2020 by American Society for Reproductive Medicine.)

Key Words: Posthumous reproduction, assisted reproduction, policy, consent, survey

Discuss: You can discuss this article with its authors and other readers at https://www.fertstertdialog.com/users/16110-fertility-and-sterility/posts/xfre-d-20-00079

Received May 5, 2020; revised June 9, 2020; accepted June 11, 2020.

E.T. has nothing to disclose. A.S. has nothing to disclose. K.G. received a grant from the Friends of Prentice. L.C.-E. has nothing to disclose. A.C. has nothing to disclose. D.L.K. serves on the scientific advisory boards of Illumina, Cradle Genomics, and Cooper Genomics. G.P.Q. has nothing to disclose.

Portions of this article were presented at the American Society for Reproductive Medicine Scientific Congress & Expo, Philadelphia, Pennsylvania, October 12-16, 2019.

Reprint requests: Gwendolyn P. Quinn, Ph.D., 550 First Ave, NBV 9N1-F, New York, New York 10016 (E-mail: Gwendolyn.quinn@nyulangone.org).
P

osthumous reproduction has historically referred to birth by a pregnant woman after the death of a male partner (1). The widespread availability of assisted reproductive technology (ART) has expanded posthumous reproduction to posthumous assisted reproduction (PAR), which includes the use of cryopreserved sperm, eggs, or embryos from deceased individuals for future family building attempts (2).

Posthumous assisted reproduction can be classified as planned or unplanned. Planned PAR involves gamete, embryo, or tissue cryopreservation before death, as with fertility preservation (FP) before gonadotoxic chemotherapy or active duty military service, and includes explicit consent from the source allowing their use posthumously (3). Planned PAR is generally accepted by laypeople and people using ART (4–6).

More controversially, unplanned PAR involves perimortem or posthumous retrieval of tissue or gametes in the case of unexpected death or illness (7). Although uncommon, cases of unplanned PAR have been widely discussed in the lay press because of their ethical complexities, raising major questions about consent of the deceased and concern for offspring (8–10). Planned PAR involving cryopreservation before death has been less widely discussed.

As reproductive medicine providers face increasing requests for both planned and unplanned PAR, and as these cases become more publicized and litigated (11, 12), the American Society for Reproductive Medicine (ASRM) Ethics Committee has suggested that ART programs develop clear policies outlining the circumstances under which they would participate in PAR (13). Despite clear recommendations, however, the widespread adoption of institutional policies is not clear. Our objective was to examine the participation of Society for Assisted Reproductive Technology (SART) member clinics in planned and unplanned PAR, and to assess the presence and content of policies toward posthumous reproduction using oocytes and embryos among those clinics.

MATERIALS AND METHODS

This study was deemed non–human subjects research by self-certification through our institutional review board. We performed a cross-sectional web-based questionnaire study of SART clinics nationwide. We identified all SART member clinics using its online database, and we included only clinics when the medical directors were members of ASRM with accessible e-mails. The survey was administered by e-mail to the medical director of each clinic and included cover letter with a link to a Qualtrics survey. Clinic contact information was extracted from the SART website and ASRM membership data. The survey was administered through a modified Dillman method, with three e-mail invitations to complete the survey sent out between April and May 2018. All survey data were anonymously collected and recorded.

The survey consisted of 33 multiple choice questions and 2 open-ended questions separated into 4 sections. For the purposes of the survey, posthumous reproduction was defined as “the creation of a pregnancy when one or both biological parents are deceased.” The first section addressed practice characteristics of each clinic, including clinic state, clinical volume, and experience with cases of posthumous reproduction. The second section addressed the presence and content of policies toward posthumous reproduction, and whether clinics did not have a policy, clinic preferences and practices were assessed. The third and fourth sections addressed policies toward fertility preservation and oocyte and embryo disposition, which could include provisions for posthumous use or transferred control of oocytes and embryos. The third section addressed eligibility criteria for embryo or oocyte cryopreservation. The fourth section addressed how clinic consent documents addressed embryo and oocyte disposition after a patient’s death. The questionnaire allowed for participants to upload their clinic’s policies or consent documents, and the final open-ended question invited free responses. The complete survey is available in Supplemental Appendix 1 (available online).

The associations of clinic characteristics with policy presence and content were assessed, where appropriate, using Fisher’s exact test. Specifically, the association of having a policy toward posthumous reproduction with clinic characteristics including in vitro fertilization (IVF) cycle volume, cancer-related oocyte cryopreservation volume, cancer-related embryo cryopreservation volume, volume of embryo transfers after FP related to a cancer diagnosis, and participation in cases of PAR (coded as participated or not participated). Association of past participation in cases of PAR with aforementioned clinic characteristics was also assessed. Incomplete responses or responses of “not sure” were treated as missing in these analyses.

RESULTS

Of the 386 SART clinics in the SART database at the time of distribution, 332 clinics were included. All clinic medical directors were sent the survey three times. Sixty-two clinics completed the questionnaire, for a response rate of 18.7%.

Clinic practice characteristics are shown in Table 1. Clinic respondents were geographically diverse, with 28 states represented. The distribution of private practice versus university affiliated clinics was reflective of SART clinics overall (14).

Volume was also diverse, with a range of IVF volumes. Number of cycles related to fertility preservation was low, although oocyte cryopreservation was more common than embryo cryopreservation. Nearly 60% of clinics had performed <10 embryo transfers after medical fertility preservation.

Of clinics who responded, 42.4% (n = 25) had participated in any cases of posthumous reproduction in the previous 5 years; this represented 6.5% of SART clinics overall. More than half (58.6%, n = 30) reported they had a policy toward PAR using oocytes and embryos. There were few patterns associated with clinic policy toward PAR or clinic exposure to PAR. The presence of a policy toward PAR was not associated with IVF cycle volume, cancer-related oocyte cryopreservation volume, cancer-related embryo cryopreservation volume, volume of embryo transfers after FP related to a cancer diagnosis, or participation in cases of PAR (P > .05). The volume of embryo transfers performed related to a cancer
diagnosis was associated with clinic exposure to PAR ($P = .014$). There was no significant association of clinic exposure to PAR with IVF cycle volume, cancer-related oocyte cryopreservation volume, or cancer-related embryo cryopreservation volume.

Of those with a policy, 55.9% (n = 19) reported using that policy in practice. Those with a policy had variable policy content (Table 2). Nearly all required prior written consent from the deceased for use of cryopreserved oocytes (96.7%, n = 29) and embryos (93.3%, n = 28) for PAR, and only 50% (n = 15) also required consent from the surviving biological parent for use of cryopreserved embryos. Forty-one percent (n = 13) of those with a policy specified a waiting period or bereavement period after a patient’s death and before the use of stored embryos or oocytes, as recommended by ASRM [13]. More than half (51.6%, n = 16) of clinics did not address a waiting period in their policy. Of those who specified a bereavement period, 61.5% (n = 8) specified the period to be between 6 months and 1 year, and 30.8% (n = 4) specified the period be >1 year. When asked if the clinic’s policy specified a time frame after a patient’s death during which the surviving partner or non-partner recipient must request the deceased patient’s cryopreserved oocytes or embryos for use, and after which the oocytes or embryos cannot be requested, 83.3% (n = 25) reported their policy specified no such time limit, and one clinic reported a time limit of 6 months. Nine clinics (30%) reported their policy addressed perimortem retrieval of oocytes or ovarian tissue from a dying patient, as would be the case in a sudden-onset life threatening condition, whereas 21 (70%) did not address this scenario. Six clinics (30%) reported their policy addressed perimortem retrieval of oocytes or ovarian tissue from a dying patient, whereas 21 (70%) did not address this scenario. Six clinics (30%) reported their policy addressed perimortem retrieval of oocytes or ovarian tissue from a dying patient, whereas 21 (70%) did not address this scenario.

Twenty-one clinics (36.8%) reported they had no policy toward PAR using oocytes and embryos. Of those without a policy, 59.1% (n = 13) reported they had considered adopting such a policy. Of note, 63.6% (n = 14) of clinics without a policy had received a request for services relating to PAR from a patient or relative of a patient in the past.

Although most clinics specified minors were eligible for FP (71.7%, n = 38), the eligibility of terminally ill patients was less clear (Table 3). Whereas 47.2% (n = 25) and 52.8% (n = 28) of clinics reported that patients not expected to survive were still explicitly eligible for FP using oocytes and embryos, respectively, many clinics did not specify whether these patients were eligible for oocyte (45.3%, n = 24) or embryo (37.7%, n = 20) cryopreservation.
Finally, almost all clinics addressed the disposition of cryopreserved oocytes (97.8%, n = 44) in the case of death of the patient and cryopreserved embryos in case of death of one (97.8%, n = 45) or both (91.3%, n = 42) of the intended parents. Details of how consent documents addressed oocyte disposition are shown in Table 4. Most clinics specified cryopreserved oocytes could be requested by an individual identified in a deceased patient’s original consent (70.5%, n = 31) or last will and testament (47.7%, n = 21). Many clinics specified that a spouse (45.5%, n = 20), partner (34.1%, n = 15), or nonrelated recipient (2.3%, n = 1) could request a patient’s cryopreserved oocytes in the event of the patient’s death. Most clinics (58.7%, n = 27) explicitly stated that cryopreserved embryos could be requested by a surviving partner, and many clinics specified that cryopreserved embryos could be requested by an individual specified in a patient’s consent documents (50%, n = 23) or last will and testament (37%, n = 17).

| TABLE 3 |
| Eligibility of minors and individuals with terminal illness for oocyte and/or embryo cryopreservation (if applicable) among clinics surveyed. |
| Patient population | Eligible | Ineligible | Not specified | Not sure |
| Minors | 38 | 71.7 | 7 | 13.2 | 6 | 11.3 |
| Patients not expected to survive to use oocytes | 25 | 47.2 | 3 | 5.7 | 24 | 45.3 |
| Patients not expected to survive to use embryos | 28 | 52.8 | 4 | 7.5 | 20 | 37.7 |

| TABLE 4 |
| Respones to questions regarding consent documents for oocyte and embryo cryopreservation for clinics surveyed. |
| Question | N | % |
| How does your consent document address cryopreserved oocyte disposition? | 34 | 75.6 |
| Oocytes will be destroyed if storage fee not paid within specified time frame | 15 | 33.3 |
| Oocytes will be destroyed in the event of death of patient | 11 | 24.4 |
| Disposable oocytes will be destroyed without written consent from patient or surviving legal partner | 8 | 17.8 |
| Disposition of oocytes is determined by the deceased patient’s last will and testament | 18 | 40.0 |
| Oocytes will be donated to research | 15 | 33.3 |
| Oocytes will be donated to prespecified recipient | 18 | 40.0 |
| Other | 6 | 13.3 |
| Who may request a patient’s cryopreserved oocytes in the case of that patient’s death? | |
| Spouse | 20 | 45.5 |
| Sexually intimate partner of deceased patient | 15 | 34.1 |
| Nonrelated recipient | 1 | 2.3 |
| Any individual specified in deceased patient’s last will and testament | 21 | 47.7 |
| Any individual specified in deceased patient’s prior written consent | 31 | 70.5 |
| Not sure | 2 | 4.5 |
| Who may request a patient’s cryopreserved embryos in the case of a donor’s death? | |
| Surviving partner with whom embryos were created | 27 | 58.7 |
| Any individual specified in deceased patient’s prior written consent | 23 | 50.0 |
| Any individual specified in deceased patient’s last will and testament | 17 | 37.0 |
| Not sure | 3 | 6.5 |

DISCUSSION

In this survey of a sample of SART clinics, nearly half of the clinics surveyed had participated in posthumous assisted reproduction cases. Despite this, nearly 40% lacked explicit institutional policies toward PAR, and many without policies had received requests for PAR. The eligibility of terminally ill patients for oocyte and embryo cryopreservation was also often not specified. Most respondents with policies did not adhere to ASRM recommendations, with nearly 70% lacking a policy toward perimortem retrieval of gametes or ovarian tissue.

Our results further confirm what the ASRM Ethics Committee has previously outlined, namely that PAR is complex and increasingly common, and clinics may not have adequate policies in place to guide their PAR practices. As only 62 clinics participated in this survey; however, the data cannot be interpreted as representative of SART clinics overall. The data do suggest that policies regarding PAR using oocytes and embryos may be lacking, which are consistent with a recent study (15) suggesting only 26.8% of major academic medical centers had policies regarding posthumous sperm retrieval. More research is needed to capture the prevalence of not only PAR policies, but also posthumous reproduction requests and procedures in fertility clinics, and the potential need for clinics to standardize their reporting of PAR. This study takes the first steps in characterizing PAR using oocytes and embryos in reproductive medicine clinics nationwide.

The presence of PAR policies is essential in reproductive medicine clinics. As FP becomes more common, more terminally ill patients may present to ART clinics. Given recent media and legal attention to cases of posthumous reproduction, patients and their families are likely to be more aware of the
ability criteria for participation in FP was similarly variable, of those with policies, their content was variable and not uni-
i
titude informed decision-making by patients and families.
the complex ethical scenarios inherent to PAR and help facil-
survey. Ideally, concise policies could aid clinics in navigating
ministry remains concerning. A better understanding is

tative care. J Palliat Med 2011;14:895–8.
3. Knapp C, Quinn G, Bower B, Zoloth L. Posthumous reproduction and palli-

This study has limitations, particularly with regard to

tween intimate partners. Fertil Steril 2011;96:1463–6.e1.
7. Shefi S, Raviv G, Eisenberg ML, Weissenberg R, Jalalian L, Levron J, et al.
Posthumous sperm retrieval: analysis of time interval to harvest sperm. Hum Reprod 2006;21:2890–3.
8. Epker JL, de Groot VJ, Kompanje EJO. Ethical and practical considerations concerning perimortem sperm procurement in a severe neurologically damaged patient and the apparent discrepancy in validation of proxy consent in various postmortem procedures. Intensive Care Med 2012;38:1069–73.
9. Greer DM, Styer AK, Toth TL, Kindregan CP, Romero JM. Case records of the Massachusetts General Hospital. Case 21-2010. A request for retrieval of sperm. The New York Times; May 22, 2019:A20.
10. Zinkel A, Ankel F, Milbank A, Casey C, Sundheim J. Postmortem sperm retrieval in the emergency department: a case report and review of available guidelines. Clin Pr Cases Emerg Med 2019;3:405–8.
11. Stack L. Parents of West Point cadet fatally injured in accident obtain order to preserve his sperm. The New York Times; May 22, 2019:A20.
12. Sullivan P. Fertility treatments produce heirs their parents never knew. The New York Times; Aug 31, 2013:85.
13. Posthumous retrieval and use of gametes or embryos: an Ethics Committee opinion. Fertil Steril 2018;110:45–9.
14. Abusief ME, Hornstein MD, Jain T. Assessment of United States fertility clinic websites according to the American Society for Reproductive Medicine (ASRM)/Society for Assisted Reproductive Technology (SART) guidelines. Fertil Steril 2007;87:88–92.
15. Waler NJ, Clavijo RI, Brackett NL, Lynne CM, Ramasamy R. Policy on posthu-
mous sperm retrieval: survey of 75 major academic medical centers. Urology 2018;113:45–51.
16. Klein M, Licea M. These women chose to have children with their dead hus-

termination of cryopreserved oocytes and embryos in the event of the death of one or both of the intended par-
ents, suggesting that policies may be implicit, rather than
explicit. The low response rate may also suggest limited
gagement with the topic of PAR among reproductive medici-

In conclusion, in our survey of 62 SART clinics, 42% re-
ported participating in cases of PAR in the past 5 years, and
37% lacked policies toward PAR to help guide their practice.
Of those with policies, their content was variable and not un-
iformly adherent to ASRM Ethics Committee Guidelines. Elig-

- possibility of PAR (11, 12, 16). Discussions of oocyte and em-
broo disposition, including the possibility of posthumous
reproduction, are essential to counseling these patients, and
clinics should have policies in place to help systematically
address these cases.

Only three-fourths of clinics surveyed explicitly include
minors in their eligibility criteria for FP treatment. This may
suggest that minors are excluded from pursuing FP in many
clinics, which may contribute to underutilization of FP
among adolescent and young adult (AYA) cancer patients.
Similarly, if minor eligibility for FP is not addressed, clinics
may also not address the disposition of stored minor gametes.
Future research should better examine how clinics address the
disposition of stored minors’ gametes. The ASRM recom-
mends minor gametes be destroyed upon death of the minor;
however, this may not be standard practice. Although use of
minor gametes for posthumous reproduction was not ade-
quately explored by this study, clear policies at a national
and institutional level are likely necessary to help navigate
the ethical challenges inherent to minor reproduction (17).

This study has limitations, particularly with regard to
generalizability. The number of respondents was low, and
represented a minority of all SART clinics. This exposes the
data to significant nonresponse and sampling bias. Some of
the heterogeneity in our results may be due to expected var-
ation in practice patterns across reproductive medicine
clinics. The survey methodology also presents potential social
desirability bias, as this survey invited clinics to self-report on
practices, and respondents may have been likely to report
what they knew to be ASRM guidelines rather than their
actual clinic practices. An additional issue warranting further
research is the extent to which state laws regarding storage
and disposition of gametes may affect policy. Given these
limitations, these results should be interpreted with caution.

The low rates of adoption or creation of policy by respon-
dent clinics remains concerning. A better understanding is
needed on how national guiding organizations, like ASRM,
can facilitate improved reporting of PAR cases and uptake
of clinic PAR policy. Although many clinics surveyed did
not explicitly address posthumous reproduction, >90% ad-
dressed the disposition of cryopreserved oocytes and embryos
in the event of the death of one or both of the intended par-
ents, suggesting that policies may be implicit, rather than
explicit. The low response rate may also suggest limited
engagement with the topic of PAR among reproductive medici-

REFERENCES

1. Hashiloni-Dolev Y, Schicktanz S. A cross-cultural analysis of posthumous reproduction: the significance of the gender and margins-of-life perspec-
tives. Reprod Biomed Soc Online 2017;4:21–32.
2. Lawson AK, Zweifel JE, Klock SC. Blurring the line between life and death: a
review of the psychological and ethical concerns related to posthumous-
assisted reproduction. Eur J Contracept Reprod Heal Care 2016;21:339–46.
3. Knapp C, Quinn G, Bower B, Zoloth L. Posthumous reproduction and palli-

care. J Palliat Med 2011;14:895–8.
4. Barton SE, Correa FA, Shalev S, Missmer SA, Lehmann LS, Shah DK, et al.

Population-based study of attitudes toward posthumous reproduction. Fertil Steril 2012;98:735–40.e5.
5. Cote S, Affdal AO, Kadoch IJ, Hamet P, Ravitsky V. Posthumous reproduc-

with surplus in vitro fertilization embryos: a study exploring users’

choices. Fertil Steril 2014;102:1410–5.
6. Nakhuda GS, Wang JG, Sauer MV. Posthumous assisted reproduction: a sur-

vey of attitudes of couples seeking fertility treatment and the degree of
agreement between intimate partners. Fertil Steril 2011;96:1463–6.e1.
7. Shefi S, Raviv G, Eisenberg ML, Weissenberg R, Jalalian L, Levron J, et al.
Posthumous sperm retrieval: analysis of time interval to harvest sperm. Hum Reprod 2006;21:2890–3.
8. Epker JL, de Groot VJ, Kompanje EJO. Ethical and practical considerations concerning perimortem sperm procurement in a severe neurologically damaged patient and the apparent discrepancy in validation of proxy con-

sent in various postmortem procedures. Intensive Care Med 2012;38:
1069–73.
9. Greer DM, Styer AK, Toth TL, Kindregan CP, Romero JM. Case records of the
Massachusetts General Hospital. Case 21-2010. A request for retrieval of

sperm from a 36-year-old woman with anoxic brain injury. N Engl J Med
2010;363:276–83.
10. Zinkel A, Ankel F, Milbank A, Casey C, Sundheim J. Postmortem sperm
retrieval in the emergency department: a case report and review of available
guidelines. Clin Pr Cases Emerg Med 2019;3:405–8.
11. Stack L. Parents of West Point cadet fatally injured in accident obtain order to
preserve his sperm. The New York Times; May 22, 2019:A20.
12. Sullivan P. Fertility treatments produce heirs their parents never knew. The
New York Times; Aug 31, 2013:85.
13. Posthumous retrieval and use of gametes or embryos: an Ethics Committee
opinion. Fertil Steril 2018;110:45–9.
14. Abusief ME, Hornstein MD, Jain T. Assessment of United States fertility clinic
websites according to the American Society for Reproductive Medicine (ASRM)/Society for Assisted Reproductive Technology (SART) guidelines. Fertil Steril 2007;87:88–92.
15. Waler NJ, Clavijo RI, Brackett NL, Lynne CM, Ramasamy R. Policy on posthu-
mous sperm retrieval: survey of 75 major academic medical centers. Urology
2018;113:45–51.
16. Klein M, Licea M. These women chose to have children with their dead hus-

bards’ sperm. New York Post; July 29, 2017.
17. Fertility preservation and reproduction in patients facing gonadotoxic ther-

apies: an Ethics Committee opinion. Fertil Steril 2018;110:380–6.